Patent ID: 8394828

Claim:
A compound of Formula (I): wherein: R 1 is a substituent independently selected from the group consisting of hydrogen; hydroxy; halogen; C 1-8 alkanyl optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 1-8 alkanyloxy optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; fluorinated alkanyloxy; fluorinated alkanyl; C 1-8 alkanylthio optionally substituted with one or more substituents independently selected from the group consisting of halogen, fluorinated alkanyl and C 1-8 alkanyloxy; C 3-8 cycloalkanyl; C 3-8 cycloalkanyloxy; nitro; amino; C 1-8 alkanylamino; C 1-8 dialkanylamino; C 3-8 cycloalkanylamino; cyano; carboxy; C 1-7 alkanyloxycarbonyl; C 1-7 alkanylcarbonyloxy; C 1-7 alkanylaminocarbonyl; C 1-7 alkanylcarbonylamino; diC 1-7 alkanylaminocarbonyl; and formyl; wherein the heteroatom contained in the quinoline ring of Formula (I) is optionally substituted with an oxo substituent; m is 0, 1 or 2; R 2 is hydrogen or C 1-8 alkanyl; L is a direct bond or C 1-4 alkyldiyl optionally substituted with a substituent selected from the group consisting of C 1-8 alkanyl, C 3-8 cycloalkanyl and phenyl optionally substituted with one to three substituents independently selected from the group consisting of C 1-8 alkanyl, halogen, C 1-8 alkanyloxy, hydroxy, fluorinated alkanyl, fluorinated alkanyloxy, amino, di(C 1-3 )alkanylamino, and C 1-3 alkanylamino; R 3 is selected from the group consisting of pyrrolyl, pyridyl, furyl, thienyl, phenyl and cyclohexyl; R 4 is independently selected from the group consisting of C 1-12 alkanyl, C 4-8 alkanyloxy, C 3-8 cycloalkanyloxy, C 1-8 alkanylamino, C 3-8 cycloalkanylamino, C 3-14 cyclic heteroalkanyl, C 1-6 fluorinated alkanyl and —N(R 5 )(R 6 ); or when n is 2 or 3, optionally two R 4 substituents taken together form a C 3-14 cyclic heteroalkyl or C 3-14 cyclic alkanyl; R 5 is hydrogen, C 1-16 alkyl, alkanylcarbonyl or arylcarbonyl; R 6 is C 4-16 alkyl, alkanylcarbonyl, C 1-3 alkyl substituted with a substituent selected from the group consisting of pyrrolyl, furyl, thienyl, phenyl, and furyl, or arylcarbonyl; or optionally R 6 and one of R 4 taken together form a saturated or partially unsaturated cyclic heteroalkyl or a heteroaryl; or R 5 and R 6 optionally taken together form a bridged or non-bridged cyclic heteroalkanyl, wherein said heteroalkanyl is optionally substituted with C 1-6 alkanylcarbonyl; wherein the alkanyls in any of the foregoing alkanyl-containing substituents of R 4 , R 5 or R 6 are optionally and independently substituted with pyrrolyl, furyl, thienyl, phenyl, furyl, C 1-4 alkylpyrrolyl, C 1-4 alkylpyridyl, C 1-4 alkylthienyl, C 1-4 alkylphenyl, or C 1-4 alkylfuryl; n is 1, 2 or 3; Z is O or S; and enantiomers, diastereomers, tautomers, and pharmaceutically acceptable salts thereof.